ARCA has an exclusive partnership with The Laboratory Corporation of America (LabCorp®) to develop and commercialize a companion genetic diagnostic to aid in prescribing bucindolol, a genetically-personalized heart failure drug in development by ARCA. The new test identifies common genetic variations of the alpha-2c and the beta-1 adrenergic receptors that regulate the human heart. LabCorp is one of the world’s leading diagnostic laboratories.

ARCA’s development of the first genetically-personalized cardiovascular therapy—bucindolol—is predicated on important discoveries in the field of cardiovascular genetics. ARCA has licensed diagnostic technology related to these discoveries from CardioDx, Inc., a leading company in the emerging field of companion diagnostics.




ARCA’s founding scientists are affiliated with the University of Colorado, and important biotechnology that is under development by ARCA had its origins in University Laboratories. ARCA is proud of its longstanding partnership and licensing agreement with the University.